Speciality Medicines Limited operates in the pharmaceutical sector, primarily engaged in marketing, distribution, export and contract manufacturing of pharmaceutical formulations. The company earns revenue through the sale of generic medicines and pharmaceutical products across multiple therapeutic segments. Its product portfolio covers treatments for cardiology, dermatology, respiratory diseases, infections, neurological disorders and chronic conditions. The company operates with a diversified business model involving loan-license manufacturing arrangements and global product registrations to expand its reach in international markets.

The company operates through corporate and operational facilities in Ahmedabad and Mumbai, which handle business operations, distribution, regulatory compliance and international trade. It holds multiple pharmaceutical distribution and manufacturing licenses under the Drugs and Cosmetics Act, enabling it to sell, stock and distribute medicines across India. The company also uses loan-license manufacturing arrangements with third-party manufacturing facilities, such as a facility located at Balasar, Mehsana in Gujarat, owned by Uniza Lifecare Private Limited.

Speciality Medicines Limited has developed a large and diversified pharmaceutical product portfolio. As of October 31, 2025, the company had more than 900 products across therapeutic segments such as antibiotics, antivirals, anti-hypertensives, dermatology, respiratory drugs, NSAIDs and urology treatments. The company operates under different brand names globally and has 7 products already registered overseas, while 54 products are under registration in five countries, which may contribute to future revenue growth.

The company plans to expand its capabilities by setting up a dedicated Research and Development (R&D) centre. This centre will include laboratories, pilot manufacturing units, stability chambers and analytical equipment such as HPLC and GC instruments. The R&D facility will support formulation development, analytical testing, product validation and scale-up processes. The centre will also help develop controlled-release tablets, fixed-dose combinations and improved formulations to enhance the company’s product portfolio and strengthen long-term innovation capability.

Employee and Banker
As of February 28, 2026, the company had 18 full time employees. The Banker to the Company is Kotak Mahindra Bank Limited.

Management and Growth Vision

The company is led by promoters Parth Goyani (Chairman and Managing Director) and Sumit Goyani (Whole-time Director), who have played a key role in building the company’s pharmaceutical portfolio and expanding its business operations since incorporation. Under their leadership, the company has developed a diversified pharmaceutical product range and established international market registrations.

The management strategy focuses on three major growth pillars:

1. Expansion of product portfolio across new therapeutic categories and niche generic medicines.
2. Global expansion through product registrations in multiple international markets.
3. Strengthening in-house R&D capabilities to develop new formulations and differentiated dosage forms.

To support these initiatives, the company plans to invest in the establishment of a modern R&D centre. This facility will help the company reduce dependence on external development partners and increase its ability to develop new drug formulations internally.

Funding for these expansion activities will be supported through IPO proceeds and internal accruals, allowing the company to strengthen research capabilities, expand product development and increase global registrations.

The management’s long-term vision is to transform the company into a global generic pharmaceutical player, focusing on high-value formulations, differentiated dosage forms and expanding exports to emerging markets.

Industry Overview

Speciality Medicines Limited operates in the global pharmaceutical industry, which is one of the largest and fastest-growing healthcare sectors worldwide.

According to industry estimates, the global pharmaceutical market was valued at USD 1,507.6 billion in 2023 and is estimated to reach USD 1,690.7 billion in 2024. The industry is expected to grow at a compound annual growth rate (CAGR) of 6.54% between 2025 and 2030, reaching approximately USD 2,472.6 billion by 2030.

Growth in the pharmaceutical industry is driven by several key factors:

• Rising prevalence of chronic diseases such as diabetes, cardiovascular disorders and cancer.
• Increasing demand for generic medicines and biosimilars, especially in developing economies.
• Expanding healthcare infrastructure and government healthcare programs across emerging markets.
• Continuous innovation in biotechnology, biologics and personalized medicine.

The pharmaceutical market shows strong regional dynamics:

• North America remains the largest pharmaceutical market due to strong healthcare spending and advanced therapies.
• Europe represents a mature market with stable growth driven by generic adoption.
• Asia-Pacific, including India, is one of the fastest-growing regions due to rising healthcare access and manufacturing capabilities.
• Middle East, Africa and Latin America are emerging export markets with strong demand for affordable generic medicines.

India plays a major role in the global pharmaceutical supply chain. The country is known as the “pharmacy of the world” because of its strong generic drug manufacturing capability and cost-efficient production ecosystem. Indian pharmaceutical companies export medicines to more than 200 countries, creating a strong opportunity for export-oriented businesses like Speciality Medicines Limited.

Major Risk Factors

1. Dependence on Third-Party Manufacturing

The company relies on loan-license manufacturing arrangements with external manufacturers for producing pharmaceutical products. Any disruption in these third-party manufacturing facilities could impact production, supply chain continuity and overall revenue generation.

2. Regulatory Compliance Risk

The pharmaceutical industry is highly regulated by authorities such as CDSCO and international regulatory bodies. Failure to comply with regulatory requirements, licensing rules or quality standards could result in product bans, penalties or suspension of operations.

3. High Competition in Generic Drugs

The global generic pharmaceutical industry is highly competitive, with many domestic and international players offering similar products. Intense competition may lead to pricing pressure and lower profit margins for the company.

4. Product Registration Risk

The company is pursuing international product registrations, with several products currently under approval in different countries. Delays or rejections in regulatory approvals may impact the company’s expansion strategy and future revenue opportunities.

5. Dependence on Product Portfolio Performance

Although the company has more than 900 pharmaceutical products, revenue may still depend heavily on the performance of certain key products. Declining demand or pricing pressure for these products could affect overall financial performance.

6. Foreign Market Expansion Risk

The company plans to expand through exports and overseas product registrations. However, foreign markets involve risks such as currency fluctuations, regulatory changes and geopolitical uncertainties, which may impact export revenue.

7. Early Stage Company Risk

Speciality Medicines Limited was incorporated in 2021, making it a relatively young pharmaceutical company. Limited operating history may create uncertainties regarding long-term profitability and scalability of the business model.

Key Strengths and Opportunities

1. Large Diversified Product Portfolio

The company has developed a portfolio of more than 900 pharmaceutical products, covering multiple therapeutic segments such as antibiotics, dermatology, respiratory and cardiovascular medicines. This diversification reduces dependency on a single product category.

2. Growing Global Registration Pipeline

The company already has 7 products registered in international markets, while 54 products are under registration in five countries. This pipeline can significantly expand export revenue once approvals are obtained.

3. Asset-Light Manufacturing Model

By using loan-license manufacturing partnerships, the company operates with an asset-light business model, allowing it to scale production without heavy capital investment in manufacturing infrastructure.

4. Planned Investment in R&D

The company’s plan to establish a dedicated R&D centre will strengthen its product development capabilities. This will enable the company to develop new formulations, improve existing medicines and create differentiated pharmaceutical products.

5. Strong Industry Growth Outlook

The global pharmaceutical industry is expected to grow to USD 2.47 trillion by 2030, creating long-term demand for generic medicines and pharmaceutical exports. This industry growth provides significant expansion opportunities.

6. Experienced Promoter Leadership

The promoters Parth Goyani and Sumit Goyani have been actively involved in the company since its incorporation. Their experience in pharmaceutical operations and international markets provides strategic direction for business expansion.